Impact of histologic grading on survival in the SWOG S0016 follicular lymphoma cohort
|
|
- Sherman Logan
- 5 years ago
- Views:
Transcription
1 Published Ahead of Print on February 22, 2018, as doi: /haematol Copyright 2018 Ferrata Storti Foundation. Impact of histologic grading on survival in the SWOG S0016 follicular lymphoma cohort by Lisa M. Rimsza, Hongli Li, Rita M. Braziel, Catherine M. Spier, Daniel O. Persky, Jennifer Dunlap, Michael LeBlanc, Nancy Bartlett, John P. Leonard, Sonali M. Smith, Oliver W. Press, and Jonathan W. Friedberg Haematologica 2018 [Epub ahead of print] Citation: Lisa M. Rimsza, Hongli Li, Rita M. Braziel, Catherine M. Spier, Daniel O. Persky, Jennifer Dunlap, Michael LeBlanc, Nancy Bartlett, John P. Leonard, Sonali M. Smith, Oliver W. Press, and Jonathan W. Friedberg. Impact of histologic grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica. 2018; 103:xxx doi: /haematol Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.
2 Impact of histologic grading on survival in the SWOG S0016 follicular lymphoma cohort Authors: Lisa M. Rimsza 1, Hongli Li 2, Rita M. Braziel 3, Catherine M. Spier 4, Daniel O. Persky 5, Jennifer Dunlap 3, Michael LeBlanc 2, Nancy Bartlett 6, John P. Leonard 7, Sonali M. Smith 8, Oliver W. Press 2, Jonathan W. Friedberg 9 1 Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona, USA 2 Fred Hutchinson Cancer Research Center, Seattle, WA, USA 3 Department of Pathology, Oregon Health Sciences University, Portland, OR, USA 4 Department of Pathology, University of Arizona, Tucson, AZ, USA 5 University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA 6 Washington University-Siteman Cancer Center, St. Louis, MO, USA 7 Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, USA 8 Department of Medicine, University of Chicago, Chicago, IL, USA 9 James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA Corresponding Author: Lisa M. Rimsza, M.D E. Shea Blvd, CRB Scottsdale, AZ rimsza.lisa@mayo.edu Phone:
3 Summary: This study examined the impact of higher grade follicular lymphoma (FL) on early progression and survival as well as the reproducibility of grading in a large prospective, phase III randomized intergroup trial, S0016, comparing 6 cycles of CHOP-R with 6 cycles of CHOP followed by iodine I-131 tositumomab radioimmunotherapy (RIT). We show a lack of correlation between histologic grade on patient outcome in the rituximab plus doxorubicin-containing chemotherapy era; and that grade is often revised, and lowered, during expert hematopathology review. Other biomarkers of early progression should be sought for FL. Introduction: Follicular lymphoma (FL) is a complex disease with variable histologic appearance and clinical outcome. There are clinical and genetic indices with prognostic capability, including the FL International Prognostic Index (FLIPI) and the more recent M7-FLIPI, which incorporates the mutation status of 7 genes with superior power to distinguish patient risk.(solal-celigny et al, 2004) (Pastore et al, 2015) In addition to baseline prognostic tools, early progression of disease at 24 months (EFS24) following R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy is a powerful predictor of overall survival. (Casulo et al, 2015) Prior to these various methods, the original histologic grading scheme was developed and is still retained in the revisions to the World Health Organization (WHO) lymphoma classification scheme.(mann & Berard, 1983;Swerdlow et al, 2016) Per current World Health Organization criteria, FL is divided into grades based on the average number of centroblasts from 10 representative high power fields (HPF) taking into account areas with both few and frequent centroblasts. Grades 1 and 2, contain an average of 0-5 and 6-15 centroblasts per HPF respectively, and are now considered together as low grade (hereafter referred to as FL1/2). Grade 3 with greater than 15 centroblasts per HPF, is further subdivided into 3A with admixed centrocytes and 3B without admixed centrocytes with the latter representing an essentially pure population of centroblasts. Using current criteria, FL3A and FL3B must demonstrate a follicular pattern (otherwise the diagnosis is moved into the diffuse large B cell lymphoma category). Although centroblast counts have been a staple of FL grading since the 1980s, the reproducibility of this method is debatable and the methods somewhat
4 complex and time-consuming.(metter et al, 1985;LaCasce et al, 2008) Furthermore, there are conflicting reports about whether there is a significant biological or survival difference between grades 3A and 3B. Some reports note that survival is similar while others find that FL3B has unique biological features.(ott et al, 2002;Wahlin et al, 2012) These conflicting data challenge the clinical utility of grading distinctions with current therapeutic options. The importance of FL grade has not been examined in a large uniformly treated cohort, particularly using progression of disease within 2 years after diagnosis, which is strongly associated with poor outcomes in patients receiving first-line R- CHOP.(Casulo et al, 2015) Previously, the SWOG Cooperative Group conducted a Phase III randomized intergroup trial S0016, which at initial publication, demonstrated no significant improvement in progression free (PFS) survival between the 2 arms (although PFS and overall survival, OS, were outstanding on both arms). (Press et al, 2013a;Press et al, 2013b) Recently, the 10 year update on the trial, demonstrated a PFS, but not OS benefit in the Bexxar arm. (Shadman et al, 2016) A subsequent S0016 paper evaluated clinical factors and found lactate dehydrogenase (LDH), beta 2 microglobulin, and FLIPI scores significantly correlated with outcome, however, did not address grade or histologic pattern. (Press et al, 2013a). S0016 is an excellent cohort for assessment of the prognostic significance of FL grading and pattern due to the use of immunochemotherapy, uniform treatment and outcome data, and centralized pathology review. We therefore sought to evaluate whether FL grading continues to be important clinical parameter in the modern treatment era. Methods: We previously confirmed the diagnosis of FL for S0016 at the time of study closure.(press et al, 2013b) This is a mature cohort with a median follow up of 10.2 years (range 50 days to 15.3 years). Briefly, the available slides and associated Pathology reports were reviewed by one of 3 SWOG Lymphoma Committee Pathologists (RMB, CMS, and LMR) for eligibility per recently revised WHO criteria.(swerdlow et al, 2016) Due to the known, high reproducibility of diagnosis of FL1/2, if the reviewing SWOG Pathologist agreed with the original diagnosis of FL1/2, no further review was conducted. If the SWOG Pathologist changed the diagnosis or changed the grade, the case was brought to consensus review, during which all 3 SWOG Pathologists reviewed the case at a multi-headed microscope, discussed the findings, and agreed on the final
5 diagnosis and grade. In addition, due to the known low reproducibility of FL3, all FL3A and FL3B cases were confirmed by the panel. (LaCasce et al, 2008) For the survival analyses according to grade the SWOG Pathologist review diagnoses were used. Cases with grade 1/2 were considered together as low grade; cases of pure grade 3A were considered 3A; cases with mixed low and high grades (combinations of grade 1/2 with grade 3A) were included in the 3A category. A single case of pure FL3B was excluded due to low number. Cases with mixed FL and DLBCL were considered DLBCL and not part of this FL survival analysis. Survival was assessed using the methods of Kaplan and Meier. (Kaplan EL & Meier P, 1958) We estimated 10 year PFS and OS and compared the results with a log-rank test. Results: For survival analyses, the SWOG Lymphoma Pathology reviewers consensus diagnoses were used. A total of 491 patients were assessed for histologic grade, of which 452 (92.0%) patients had grade 1/2, and 39 (7.9%) patients had grade 3A. No cases were considered pediatric-type FL, since this trial was limited to adult patients with advanced stage disease. The distribution of FL1/2 or 3A cases was similar between treatment arms (91.8% and 8.1% for CHOP-immunochemotherapy and 92.2% and 7.7% for CHOP-R respectively). These results are summarized in Table 1. The estimated 10-year OS was 79% for FL 1/2 (95% CI: 74.6 to 82.6%); and 68% for FL3A (95% CI: 50.3 to 80.5%) (log-rank p-value ). In addition, the estimated 10-year PFS was 49% for FL 1/2 (95% CI: 44.5 to 54.1%); and 47% for FL3A (95% CI:30.1 to 61.7%) (log-rank p-value ). Survival curves are illustrated in Figure 1. A total of 521 cases were submitted with a diagnosis of FL. Of these, 497 (95.4%) had a definitive grade in the diagnostic line or description from the submitted outside pathology report. Of the 497 graded FL cases, changes to that grade occurred in 54/497 (10.8%). Interestingly, 45 of these 54 (83.3%) changes were down grades from grade FL3A to FL1/2, while in contrast, only 9/54 (16.7%) were upgraded from an original diagnosis of FL1/2 to FL3A. Altogether, these data indicate that most FL grading changes by the SWOG review panel were decreases in the FL grade and highlighted a bias towards higher grades in community practice. Microscopic review revealed that the down-graded FL cases often had either large centrocytes, sclerosis that may distort cell cytology, or many follicular dendritic cells, which may have made them particularly challenging. Discussion: This study examined both the impact of higher grade FL on early progression and survival as well as the reproducibility of grading in a large prospectively treated cohort. We show that (1) the impact of histologic grading on patient outcome in the rituximab plus doxorubicin- containing chemotherapy era is
6 negligible and that (2) there is a tendency to over-grade FL. In the United States, bendamustine has largely replaced CHOP as the preferred chemotherapy platform newly diagnosed advanced stage FL, based upon randomized data suggesting similar to improved PFS and a better toxicity profile.(flinn et al, 2014;Rummel et al, 2013) These two randomized trials excluded patients with grade 3 FL. In agreement with Koch et. al, 2016, our results suggest that, at least when doxorubicin-containing chemotherapy with an anti-cd20 monoclonal antibody are utilized, grade 3A has similar outcome to grade 1/2 disease. These observations should be validated in a cohort of patients treated with R-bendamustine. Similar to an earlier study, there were no cases showing combinations of both FL3A and FL3B stressing that these two diseases likely have different pathogenesis. (Koch et al, 2016) Challenges to the reproducibility in grading as previously reported in the literature were again found in this study. The most frequent change was downgrading of originally denoted FL3A or 3B cases to FL1/2. Our findings highlight a tendency to over-grade FL in routine practice most likely due to the difficulty in cytologically separating the various cell types within the germinal center environment. Various centroblast mimics such as large centrocytes (large cleaved cells but without nucleoli) or follicular dendritic cells (single or binucleated cells with clear nuclei and centrally placed eosinophilic nucleoli) can be difficult to identify and exclude. In agreement with our findings, Grade 3 FL was one of the least reproducible of the lymphoma diagnostic categories in the National Cancer Care Network database study.(lacasce et al, 2008) As the FL field moves forward, integrated biomarkers such as clinical features with genomics and/or expression markers are likely to be more important than grade in prognosis, and may also provide predictive information for specific therapies. Acknowledgements: LMR, RMB, CMS, JD, and HL performed the research. LMR, OP, JF, HL designed the study. HL and ML analyzed the data. LMR and HL wrote the paper. DOP, SMS, JF critically revised the manuscript. All authors approved of the submitted final version.
7 & Z E / E /, E hdddedeee hdddedede hdddedede hdddededd hddddedd hddddded ' ^ < d E /, ' ^ < Financial interest disclosures: None.
8 Z d D <> Z & > Z W s W W, Z & E > ^ : K dddd dd dd ddde dddd d & /t : Z < ^ Z Z,KW Z sw E,> D> Z/',d dddd ddd de dedd dedd d < > D W E : ^ dede dd ded dde ded d < <, D d ' '>^' ^,E,> K ddde de e dddd ddde d > ^ < D & :t, E E : K ddde de dd ddde dddd e D Z t, K deed d d dee ded e D ' E E :^ D Z W W > ^ : K deed d d dd de e K ' < d > d d dddd ee dd dede dedd e W : s < Z / > K dddd de e dddd dddd dd W Kt h :D Z >D ///,KW,KWlddd Z dddd de dd eedd eedd
9 dd W Kt h :D Z >D W ///,KW,KW ddd, ^tk'^ddde : K dddd dd d ddd ddd dd Z D: E E D ',KW d > dddd ded eeed dddd dddd dd ^ D >, Z >D K W h & > W d,kww Z,KWW ddd / d > d & W // Z ^ ^tk'ddde ddde dde dd ede dd ^ W Z W W & dddd ddd d ddde dded dd ^ ^, W ^ d ddde t, K ddde dde dd dded dded de t z K < t,k ddd :, dddd dde d ddd ddd
10 d d W W,KW Z,KW Z/d d ded dddl dde ddd dl ddd dddl &>d d ddd edl dde ed dl ddd ed el &>d de e el de e el dd e dl W ^ ' d & dd W&^ edl/ W &>d d ddd dde del dd dl dd dl &>d de dd del dd dl ed el d eeee K ^ ' d & dd K^ edl/ W &>d d ddd ed eel ed el ed el &>d de dd eel dd dl ed dl d deed,kwl Zl Z/dl &>l /l K^l W&^l Figure legend: Survival stratified by histologic grade. Figure 1A: Overall survival according to histologic grade. Figure 1B: Progression free survival according to histologic grade.
11
Nocturnal enuresis and K+ transport in red blood cells from patients with sickle cell anaemia
Published Ahead of Print on September 1, 2016, as doi:10.3324/haematol.2016.149500. Copyright 2016 Ferrata Storti Foundation. Nocturnal enuresis and K+ transport in red blood cells from patients with sickle
More informationC-reactive protein and risk of venous thromboembolism: results from a population-based case-crossover study
Published Ahead of Print on April 19, 2018, as doi:10.3324/haematol.2017.186957. Copyright 2018 Ferrata Storti Foundation. C-reactive protein and risk of venous thromboembolism: results from a population-based
More informationSolomon Graf, MD February 22, 2013
Solomon Graf, MD February 22, 2013 Case Review of FL pathology, prognosis Grading of FL Grade 3 disease High proliferative index in grade 1/2 disease Pediatric FL Future of FL classification 57 yo man
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationImpact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia
Published Ahead of Print on December 31, 2014, as doi:10.3324/haematol.2014.115576. Copyright 2014 Ferrata Storti Foundation. Impact of additional genetic alterations on the outcome of patients with NPM1-mutated
More informationPublished Ahead of Print on April 14, 2016, as doi: /haematol Copyright 2016 Ferrata Storti Foundation.
Published Ahead of Print on April 14, 2016, as doi:10.3324/haematol.2016.143214. Copyright 2016 Ferrata Storti Foundation. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationMEETING SUMMARY ASH 2018, San Diego, USA
MEETING SUMMARY ASH 2018, San Diego, USA Prof. Stefano Luminari University of Modena and Reggio Emilia, Italy AN UPDATE ON PROGNOSTIC FACTORS IN INDOLENT LYMPHOMAS 2 DISCLAIMER Please note: The views expressed
More informationPublished Ahead of Print on November 8, 2013, as doi: /haematol Copyright 2013 Ferrata Storti Foundation.
Published Ahead of Print on November 8, 2013, as doi:10.3324/haematol.2013.088211. Copyright 2013 Ferrata Storti Foundation. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationLong-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin
Published Ahead of Print on July 13, 2017, as doi:10.3324/haematol.2017.171215. Copyright 2017 Ferrata Storti Foundation. Long-term risk of cancer development in adult patients with idiopathic aplastic
More informationImpact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia
Published Ahead of Print on May 17, 2018, as doi:10.3324/haematol.2018.191999. Copyright 2018 Ferrata Storti Foundation. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More informationAssociation of Acute Myeloid Leukemia s Most Immature Phenotype with Risk Groups and Outcomes
Published Ahead of Print on January 27, 2016, as doi:10.3324/haematol.2015.135194. Copyright 2016 Ferrata Storti Foundation. Association of Acute Myeloid Leukemia s Most Immature Phenotype with Risk Groups
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationAPOL1, Alpha thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia
Published Ahead of Print on September 22, 2016, as doi:10.3324/haematol.2016.154153. Copyright 2016 Ferrata Storti Foundation. APOL1, Alpha thalassemia, and BCL11A variants as a genetic risk profile for
More informationSplenic marginal zone NHL: Update on biology and therapy. Jonathan W. Friedberg M.D., M.M.Sc.
Splenic marginal zone NHL: Update on biology and therapy Jonathan W. Friedberg M.D., M.M.Sc. Marginal zone NHL: A Neglected Lymphoma? Marginal zone NHL/MALT; 3 rd most common B-cell NHL Al-Hamadani et
More informationHODGKIN S AND NON-HODGKIN S LYMPHOMA
HODGKIN S AND NON-HODGKIN S LYMPHOMA edited by JOHN P. LEONARD, MD Center for Lymphoma and Myeloma Weill Medical College of Cornell University New York Presbyterian Hospital New York, NY MORTON COLEMAN,
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationHow I treat High-risk follicular lymphoma
How I treat High-risk follicular lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona 1) median OS raised from 10 to 18 y 2) advanced FL remains uncurable Stanford, n = 1334
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationChoice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma
Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationHow to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma
How to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma Peter A. Riedell, MD and Brad S. Kahl, MD Abstract Follicular lymphoma (FL) is the most common
More informationOutcomes of Treatment in Slovene Follicular Lymphoma Patients
Original Study Outcomes of Treatment in Slovene Follicular Lymphoma Patients Tanja Juznic Setina, Simona Borstnar, Barbara Jezersek Novakovic Abstract The treatment outcomes of follicular lymphoma (FL)
More informationPublished OnlineFirst October 15, 2013; DOI: / CCR
Predictive Biomarkers and Personalized Medicine Clinical Cancer Research A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP Rituximab versus CHOP
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationModified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
ORIGINAL ARTICLE DOI: 10.3904/kjim.2010.25.3.301 Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma Changhoon Yoo
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationFollicular Lymphoma. Michele Ghielmini. Oncology Institute of Southern Switzerland Bellinzona
Follicular Lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona Conflicts of interest Astra Zeneca Roche Cellgene Mundipharma Janssen Gilead Bayer Abbvie FL remains an incurable
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationRituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma
Page 1 of 5 Home Search Study Topics Glossary Search Full Text View Tabular View No Study Results Posted Related Studies Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's
More informationMB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis
Published Ahead of Print on July 23, 2015, as doi:10.3324/haematol.2015.127001. Copyright 2015 Ferrata Storti Foundation. MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationImmunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma combined performance of multiple markers
Published Ahead of Print on June 11, 2015, as doi:10.3324/haematol.2014.120956. Copyright 2015 Ferrata Storti Foundation. Immunohistochemical differentiation between follicular lymphoma and nodal marginal
More informationCharacterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
More informationTHYROID CANCER INCIDENCE CONTINUES TO RISE BUT MORTALITY REMAINS STABLE IN YOUNG, HISPANIC AND BLACK POPULATIONS IN THE UNITED STATES
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationOutcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
British Journal of Cancer (3) 89, 36 42 & 3 Cancer Research UK All rights reserved 7 9/3 $25. www.bjcancer.com Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationReal-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era
Published Ahead of Print on April 26, 2018, as doi:10.3324/haematol.2017.185868. Copyright 2018 Ferrata Storti Foundation. Real-world treatment and outcomes among older adults with chronic lymphocytic
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationCLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE
FOR IMMEDIATE RELEASE CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE Results of Studies of BEXXAR TM Therapy Show Promise
More informationAddition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma
Original Article Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma Bo Jia 1, Yuankai Shi 1, Suyi Kang 1, Sheng
More informationIbrutinib Withdrawal Symptoms in Patients with Waldenström Macroglobulinemia
Published Ahead of Print on February 22, 2018, as doi:10.3324/haematol.2017.186908. Copyright 2018 Ferrata Storti Foundation. Ibrutinib Withdrawal Symptoms in Patients with Waldenström Macroglobulinemia
More informationRemissions after long term use of romiplostim for immune thrombocytopenia
Published Ahead of Print on September 1, 2016, as doi:10.3324/haematol.2016.151886. Copyright 2016 Ferrata Storti Foundation. Remissions after long term use of romiplostim for immune thrombocytopenia by
More informationBendamustine for relapsed follicular lymphoma refractory to rituximab
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for relapsed follicular lymphoma refractory to rituximab Bendamustine for relapsed follicular lymphoma refractory to rituximab Contents Summary 1
More informationThe role of liposomal doxorubicin in DLBCL lymphomas. Michele Spina Aviano
The role of liposomal doxorubicin in DLBCL lymphomas Michele Spina Aviano Disclosures of Michele Spina Company name Research support Employee Consultant Stockholder Speakers bureau Advisory board Other
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationThe use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors
Publish Ahead of Print on ecember 14, 2017, as doi:10.3324/haematol.2017.180166. Copyright 2017 Ferrata Storti Foundation. The use of romiplostim in treating chemotherapy-induc thrombocytopenia in patients
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationHuman Leukocyte Antigen Class I and II Alleles and Overall Survival in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Clinical Study TheScientificWorldJOURNAL (2), 262 27 ISSN 537-744X; doi:./2/373876 Human Leukocyte Antigen Class I and II Alleles and Overall Survival in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationIl trattamento del Linfoma Follicolare in prima linea
Il trattamento del Linfoma Follicolare in prima linea Dr.ssa Carola Boccomini SC Ematologia Dr. U. Vitolo AO Città della Salute e della Scienza Torino, Italy Median follow-up 3 years Median follow-up 6
More informationThe prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials Frederick Lansigan, Dartmouth College Ian Barak, Duke University Brandelyn
More informationINSIGHT INTO THE PATHOGENESIS OF FOLLICULAR LYMPHOMA. By Dr. Abdulmohsen Alhejaily
INSIGHT INTO THE PATHOGENESIS OF FOLLICULAR LYMPHOMA By Dr. Abdulmohsen Alhejaily Insight into the pathogenesis of follicular lymphoma Dr. Abdulmohsen Alhejaily 1,2 1: Collage of Medicine and Research
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationCPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults The Benefits of the Proposition
More informationTransformed follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
Transformed follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. The past: Incidence and Outcome of Transformed NHL Steady risk of 3% per year for first 15 years of diagnosis Treatment (or lack thereof)
More informationNon Transplant-Related Treatment Options in Follicular Lymphoma
Biology of Blood and Marrow Transplantation 12:53-58 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0111$32.00/0 doi:10.1016/j.bbmt.2005.10.003 Non Transplant-Related
More informationLymphoma Committee Alliance for Clinical Trials in Oncology 2016 Beijing International Lymphoma Conference April 9, 2016 David J. Straus, M.D.
Lymphoma Committee Alliance for Clinical Trials in Oncology 2016 Beijing International Lymphoma Conference April 9, 2016 David J. Straus, M.D. Memorial Sloan Kettering Cancer Center New York, NY USA CALGB/Alliance
More informationFollicular Lymphoma 2016:
Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual
More informationMyelodyspastic Syndromes
Myelodyspastic Syndromes SUPPLEMENTARY APPENDIX Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationDiffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA
Diffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA Disclosures Consulting advice: Hospira, Bayer, Juno Therapeutics, Teva, Oncotracker, Gilead
More informationDisease progression after initial platinum-based chemotherapy
Original Article Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era A Patient-Level Analysis of Southwest Oncology Group Trials Primo
More informationAddress correspondence to: Brad S. Kahl, MD 1111 Highland Avenue, 4059 WIMR Madison, WI
Yttrium 90-Ibritumomab Tiuxetan Plus Rituximab Maintenance as Initial Therapy for Patients With High-Tumor-Burden Follicular Lymphoma: A Wisconsin Oncology Network Study Saurabh Rajguru, MD, Thorhildur
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationDigital Washington University School of Medicine. Russell Schilder Fox Chase Comprehensive Cancer Center. Arturo Molina Biogen Idec
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2004 Follow-up results of a phase II study of ibritumomab tiuetan radioimmunotherapy in patients with relapsed or
More informationAddition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
VOLUME 46 ㆍ NUMBER 2 ㆍ June 2011 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationThe international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP
www.nature.com/scientificreports Received: 24 April 2017 Accepted: 20 September 2017 Published: xx xx xxxx OPEN The international staging system improves the IPI risk stratification in patients with diffuse
More informationAndrogen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationFinal published version:
[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based
More informationTositumomab and iodine I 131 tositumomab (Bexxar ) Corixa Corporation; marketed by GlaxoSmithKline 1
Generic (Trade Name): Manufacturer: Tositumomab and iodine I 131 tositumomab (Bexxar ) Corixa Corporation; marketed by GlaxoSmithKline 1 NO. 64 OCTOBER 2005 Indication: Current Regulatory Status: In the
More informationOverview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC
2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly
More informationIs there still a role for autotransplant with follicular lymphoma in the rituximab era. Pr. Christian Gisselbrecht Hôpital Saint Louis Paris, France
COSTEM Berlin September 8-11 211. Is there still a role for autotransplant with follicular lymphoma in the rituximab era. Pr. Christian Gisselbrecht Hôpital Saint Louis Paris, France World Health Organization
More informationInhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs
Published Ahead of Print on October 14, 2016, as doi:10.3324/haematol.2016.144964. Copyright 2016 Ferrata Storti Foundation. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationABSTRACT Background Patients with clinically localized, intermediate-
CHEMOTHERAPY ALONE VS. CHEMOTHERAPY PLUS RADIOTHERAPY FOR NON-HODGKIN S LYMPHOMA CHEMOTHERAPY ALONE COMPARED WITH CHEMOTHERAPY PLUS RADIOTHERAPY FOR LOCALIZED INTERMEDIATE- AND HIGH-GRADE NON-HODGKIN S
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationDefined lymphoma entities in the current WHO classification
Defined lymphoma entities in the current WHO classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Bellinzona, January 29-31, 2016 Evolution of lymphoma classification Rappaport Lukes
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationOutcomes among US patients with diffuse large B cell lymphoma are independent of tumor Epstein Barr virus positivity or immunosuppression
Published Ahead of Print on November 23, 2017, as doi:10.3324/haematol.2017.176511. Copyright 2017 Ferrata Storti Foundation. Outcomes among US patients with diffuse large B cell lymphoma are independent
More information